Analyst Mitchell Kapoor of H.C. Wainwright reiterated a Buy rating on Intellia Therapeutics (NTLA – Research Report), retaining the price target of $30.00.
Don’t Miss TipRanks’ Half Year Sale
- Take advantage of TipRanks Premium for 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Mitchell Kapoor has given his Buy rating due to a combination of factors related to Intellia Therapeutics’ promising clinical data and financial projections. The updated two-year Phase 1 data for their drug candidate, nex-z, in treating ATTR-PN has shown significant improvements in the modified Neurologic Impairment Score (mNIS+7), suggesting a durable stabilization of the disease. This improvement positions nex-z as a potentially superior therapeutic option compared to existing treatments, contingent on the replication of results in future studies.
In addition to the clinical data, Kapoor’s valuation of Intellia is supported by a discounted cash flow analysis, which estimates an enterprise value of approximately $3.0 billion and a 12-month price target of $30 per share. The analysis assumes an 11% discount rate and a 3% terminal growth rate, reflecting the company’s focus on well-known diseases with validated targets. Furthermore, the absence of long-term debt and the potential for pipeline expansion contribute to the positive outlook. However, Kapoor notes risks such as potential setbacks in clinical trials and delays in pipeline progression.